Liver disease has emerged as a major source of morbidity and mortality in the United States with a disproportionate representation in some identifiable groups. Furthermore, unique management and treatment issues are associated with identifiable groups which have been characterized as """"""""special populations"""""""". This K-24 application demonstrates the candidate's focus on liver disease in special populations including hemophiliacs, liver transplant recipients, alcoholics and individuals with HIV infection. The etiologies of progressive liver disease are multifactorial and include viral hepatitis, drug toxicities including those associated with highly active antiretroviral therapies (HAART), alcohol, and variable levels of immunosuppression. Evidence is provided that the candidate is well equipped to provide mentorship of junior faculty and trainees within the context of his programmatic goals. This proposal includes a: 1.Description of the candidate's commitment to patient-oriented research 2. Characterization of key aspects of a mentorship program that incorporates elements of didactic training, involvement of trainees and junior faculty in ongoing research activities, and ongoing interaction between candidate and mentee to develop nascent patient based research careers. 3. Review of the specific research activities funded by NIH and the pharmaceutical industry that serve as a structural framework for patient-oriented research

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Midcareer Investigator Award in Patient-Oriented Research (K24)
Project #
Application #
Study Section
Diabetes, Endocrinology and Metabolic Diseases B Subcommittee (DDK)
Program Officer
Podskalny, Judith M,
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Cincinnati
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Welzel, Tania M; Nelson, David R; Morelli, Giuseppe et al. (2017) Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study. Gut 66:1844-1852
Abdel-Hameed, Enass A; Rouster, Susan D; Zhang, Xiang et al. (2017) Characterization of HCV NS3 Protease Variants in HCV/HIV-Coinfected Patients by Ultra-Deep Sequence Analysis: Relationship with Hepatic Fibrosis. J Acquir Immune Defic Syndr 74:353-358
Sherman, K E; Ke, R; Rouster, S D et al. (2016) Viral dynamic modelling of Hepatitis C and resistance-associated variants in haemophiliacs. Haemophilia 22:543-8
Hetta, Helal F; Mekky, Mohamed A; Khalil, Nasr K et al. (2016) Extra-hepatic infection of hepatitis C virus in the colon tissue and its relationship with hepatitis C virus pathogenesis. J Med Microbiol 65:703-12
Mehta, Minesh; Hetta, Helal F; Abdel-Hameed, Enass A et al. (2016) Association between IL28B rs12979860 single nucleotide polymorphism and the frequency of colonic Treg in chronically HCV-infected patients. Arch Virol 161:3161-9
Abdel-Hameed, Enass A; Rouster, Susan D; Ji, Hong et al. (2016) Evaluating the Role of Cellular Immune Responses in the Emergence of HCV NS3 Resistance Mutations During Protease Inhibitor Therapy. Viral Immunol 29:252-8
Sherman, Amy C; Sherman, Kenneth E (2015) Extrahepatic manifestations of hepatitis C infection: navigating CHASM. Curr HIV/AIDS Rep 12:353-61
Hetta, Helal F; Mekky, Mohamed A; Khalil, Nasr K et al. (2015) Association of colonic regulatory T cells with hepatitis C virus pathogenesis and liver pathology. J Gastroenterol Hepatol 30:1543-51
Lin, M V; Charlton, A N; Rouster, S D et al. (2014) Hepatitis C virus NS3 mutations in haemophiliacs. Haemophilia 20:659-65
Abdel-Hameed, Enass A; Ji, Hong; Sherman, Kenneth E et al. (2014) Epigenetic modification of FOXP3 in patients with chronic HIV infection. J Acquir Immune Defic Syndr 65:19-26

Showing the most recent 10 out of 43 publications